Nxera And Tempero Bio Advance Treatment For Alcohol Use Disorder With New Phase 2 Study

Nxera Pharma Co., Ltd. announced that its partner, Tempero Bio, Inc., has initiated a Phase 2 clinical trial for TMP-301, an mGluR5 negative allosteric modulator (NAM) designed to treat alcohol use disorder (AUD). This trial will evaluate the safety, tolerability, and impact of TMP-301 on alcohol consumption in AUD patients, comparing it to a placebo-controlled group. Tempero Bio was created in 2020 by the venture firm Aditum Bio to advance the clinical development of a portfolio of potent orally available mGluR5 NAMs for substance use disorders.

Matt Barnes, EVP, President of Nxera Pharma UK and Head of R&D, said in a statement, “We are excited to see another program originating from our NxWave™ discovery platform advancing into the next stage of clinical development, as our partner Tempero Bio progresses TMP-301 to a Phase 2 trial for alcohol use disorder. This asset is another example highlighting the strength of our NxWave™ platform to continue delivering innovative candidates for further development. We are expecting an important year ahead across both our partnered and in-house pipelines, with key data readouts anticipated from multiple trials and several new trials due to start.”

Under a 2020 licensing agreement, Tempero Bio obtained exclusive global rights to Nxera’s portfolio of mGluR5 NAM drug candidates, including TMP-301. In exchange, Nxera secured a strategic equity stake in Tempero Bio and is eligible for development, commercial milestone payments, and tiered royalties from future product sales. While initiating the Phase 2 trial does not trigger an immediate milestone payment from Tempero Bio to Nxera, the company confirmed that it would disclose any future milestone events that result in significant financial compensation.